Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature

References

• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Unidad de Vigilancia de VIH, Conductas de R. Mortalidad por VIH y sida en España, año 2017. Evolución 1981-2017. Centro Nacional de Epidemiología, Instituto de Salud Carlos III/ Plan Nacional sobre el Sida, Dirección General de Salud Pública, Calidad e Innovación. Madrid; 2019. Available from: https://www.mscbs.gob.es/ca/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/doc/MortalidadXVIH2017.pdf (cited 2020 May 29). • Mortality due to HIV and AIDS in Spain. Evolution 1981-2017.
   Google Scholar
• Dirección General de Salud Pública. Calidad e Innovación. Informe de evaluación. Plan estratégico de prevención y control del VIH e ITS de 2013-2016. Plan Nacional del SIDA. 2018. Available from: https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/planesEstrat/informeEvaluacion_VDweb_12Dicbre18.pdf (cited 2019 Jun 30). • Strategic plan for the prevention and control of HIV in Spain (2013-2016).
   Google Scholar
• Díaz A. Actualización epidemiológica española de los objetivos 2020. Rev Multidisciplinar del Sida. 2020;8:11–12.
   Google Scholar
• Unidad de Vigilancia de VIH, Conductas de R. Mortalidad por VIH y sida en España, año 2017. Evolución 1981-2017. Centro Nacional de Epidemiología, Instituto de Salud Carlos III/ Plan Nacional sobre el Sida, Dirección General de Salud Pública, Calidad e Innovación. Madrid; 2019.
   Google Scholar
• Glosario de Infosida.Términos relacionados con el VIH/SISA 9 edición. infoSIDA ed. US Department of Health and Human Services, HHS; 2021. Available from: https://clinicalinfo.hiv.gov/sites/default/files/glossary/Glossary-Spanish-HIVinfo.pdf ( Available from.
   Google Scholar
• Panel de Expertos de GeSIDA y División de control de VIH, ITS, Hepatitis virales y Tuberculosis. Plan Nacional sobre el SIDA. Documento de consenso de GeSIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (update 2022). GeSIDA/Ministerio de Sanidad. Available from: https://gesida-seimc.org/wp-content/uploads/2022/05/GuiaGeSIDAPlanNacionalSobreElSidaRespectoAlTratamientoAntirretroviralEnAdultosInfectadosPorElVirusDeLaInmunodeficienciaHumanaActualizacionEnero2022.pdf (cited 2022 May 30). •• GeSIDA Consensus Document/National Plan on AIDS.
   Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
   PubMed Web of Science ®Google Scholar
• Rubio-Rodríguez D, De Diego S, Pérez M, et al. The cost-effectiveness of drug treatments for advanced melanoma: a systematic literature review. PharmacoEconomics. 2017;35(9):879–893.
   PubMed Web of Science ®Google Scholar
• Biktarvy 50 mg/200 mg/25 mg film-coated tablets. Summary of Product Specifications, 2018 Jun 21. Available from: https://www.ema.europa.eu/en/documents/product-information/biktarvy-epar-product-information_en.pdf (cited 2021 Nov 19).
   Google Scholar
• Biktarvy. Assessment report. EMA/293559/2018. European Medicines Agency, 2018 Apr 26. Available from: https://www.ema.europa.eu/en/documents/assessment-report/biktarvy-epar-public-assessment-report_en.pdf (cited 2021 Nov 19). • EMA Assessment Report.
   Google Scholar
• Dovato 50 mg/300 mg film-coated tablets. Summary of product specifications, Cited 2019 Jul 1. Available from: https://www.ema.europa.eu/en/documents/product-information/dovato-epar-product-information_en.pdf (cited 2021 Nov 19). • EMA Assessment Report.
   Google Scholar
• Dovato. Assessment report. EMA/267082/2019. European Medicines Agency, 2019 Apr 26. Available from: https://www.ema.europa.eu/en/documents/assessment-report/dovato-epar-public-assessment-report_en.pdf (cited 2021 Nov 19). • EMA Assessment Report.
   Google Scholar
• Juluca 50 mg/25 mg film-coated tablets. Summary of Product Specifications, 2018 May 16. Available from: https://www.ema.europa.eu/en/documents/product-information/juluca-epar-product-information_en.pdf (cited 19 November 2021). • EMA Assessment Report.
   Google Scholar
• Juluca. Assessment report. EMA/243517/2018. European Medicines Agency, 2018 Mar 26. Available from: https://www.ema.europa.eu/en/documents/assessment-report/juluca-epar-public-assessment-report_en.pdf (cited 2021 Nov 19). • EMA Assessment Report.
   Google Scholar
• Jadad A, Moore A, Carroll D, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Controll Clin Trials. 1996;17(1):1–12.
   PubMedGoogle Scholar
• Berger VW, Alperson SY. A general framework for the evaluation of clinical trial quality. Rev Recent Clin Trials. 2009;4(2):79–88.
   PubMedGoogle Scholar
• Kityo C, Hagins D, Koenig E, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) in virologically suppressed HIV-1 infected women: a randomised, open-label, multicenter, active-controlled, phase 3, noninferiority trial. J Acquir Immune Defic Syndr. 2019;82(3):321–328.
   PubMed Web of Science ®Google Scholar
• Orkin C, DeJesus E, Sax PE, et al. GS-US-380-1490 study investigators. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020;7(6):e389–400.
   PubMed Web of Science ®Google Scholar
• CADTH. Clinical Review Report. Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/FTC/TAF) (Biktarvy). October 2018/Canadian drug expert committee recommendation. Dolutegravir/Rilpivirine (Juluca — ViiV Healthcare). Version 1.0. June, 2018.
   Google Scholar
• Deeks ED. Bictegravir/Emtricitabine/Tenofovir Alafenamide: a review in HIV-1 infection. Drugs. 2018;78(17):1817–1828.
   PubMed Web of Science ®Google Scholar
• Pham HT, Mesplède T. Bictegravir in a fixed dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications. Exp Opin Pharmacother. 2019;20(4):385–397.
   PubMed Web of Science ®Google Scholar
• Chen IW, Sun HY, Hung CC. Meta-analysis of efficacy and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide among people living with HIV. Infect Dis Ther. Cited 2021 May 11;10(3):1331–1346.
   PubMed Web of Science ®Google Scholar
• Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, Abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063–2072.
   PubMed Web of Science ®Google Scholar
• Wohl DA, Yazdanpanah Y, Baumgarten A, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, Abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e355–63.
   PubMed Web of Science ®Google Scholar
• Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390:2073–2082. /Protocol 1490: Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults. Available from: https://clinicaltrials.gov/ct2/show/NCT02607956?term=GS-US-380%E2%80%931490&draw=2&rank=1
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Arribas JR, Stephens JL, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e364–72.
   PubMed Web of Science ®Google Scholar
• Radford M, Parks DC, Ferrante S, et al. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naïve HIV patients. AIDS. 2019;33(11):1739–1749.
   PubMed Web of Science ®Google Scholar
• Eron J, Hung CC, Baril JG, et al. Brief report: virologic response by baseline viral load with dolutegravir plus lamivudine vs dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis. J Acquir Immune Defic Syndr. 2020;84(1):60–65.
   PubMed Web of Science ®Google Scholar
• Hocqueloux L, Gubavu C, Prazuck T, et al. Genital human immunodeficiency virus-1 RNA and DNA shedding in virologically suppressed individuals switching from triple- to dual- or monotherapy: pooled results from 2 randomised, controlled trials. Clin Infect Dis. 2020;70(9):1973–1979.
   PubMed Web of Science ®Google Scholar
• Punekar YS, Parks D, Joshi M, et al. Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence. HIV Med. 2021;22(6):423–433.
   PubMed Web of Science ®Google Scholar
• Wijting I, Rutsaert SL, Rokx C, et al. Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy. HIV Med. 2019;20(1):63–68.
   PubMed Web of Science ®Google Scholar
• Cadiñanos J, Montejano R, de Miguel Buckley R, et al. Risks and benefits of reducing the number of drugs to treat HIV-1 infection. Expert Opin Drug Saf. 2021;20(4):397–409.
   PubMed Web of Science ®Google Scholar
• Cento V, Perno CF. Dolutegravir plus lamivudine two-drug regimen: safety, efficacy and diagnostic considerations for its use in real-life clinical practice-A refined approach in the COVID-19 era. Diagnostics (Basel). 2021;11(5):809.
   PubMedGoogle Scholar
• Ciccullo A, Baldin G, Dusina A, et al. Efficacy and safety of dolutegravir plus lamivudine as a first-line regimen in clinical practice. AIDS Res Hum Retroviruses. 2021 Mar 19;37(6):486–488.
   PubMed Web of Science ®Google Scholar
• Greenberg L, Ryom L, Neesgaard B, et al. RESPOND study group. Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV. Clin Infect Dis. 2020;ciaa1878. DOI:10.1093/cid/ciaa1878.
   Google Scholar
• Cahn P, Madero JS, Arribas JR, et al.; GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143–155. https://clinicaltrials.gov/ct2/show/NCT02831673?term=gemini+1+dolutegravir&draw=2&rank=1Protocol GEMINI 1: An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1). Available from: https://clinicaltrials.gov/ct2/show/NCT02831673?term=gemini+1+dolutegravir&draw=2&rank=1 (cited: 02/06/2021)./Protocol GEMINI 2: An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2). Available at URL: https://clinicaltrials.gov/ct2/show/NCT02831764?term=gemini+1+dolutegravir&draw=2&rank=4 (cited: 02/06/2021).
   PubMed Web of Science ®Google Scholar
• Cahn P, Madero JS, Arribas JR, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naïve adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomised clinical trials. J Acquir Immune Defic Syndr. 2020;83(3):310–318.
   PubMed Web of Science ®Google Scholar
• Cahn P, Sierra J, Arribas JR, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment -naïve adults with HIV-1 infection- 3 -year results from the GEMINI studies Poster P018. HIV Drug Therapy: Glasgow;2020, 2020 October 6-8
   Google Scholar
• Cahn P, Sierra Madero J, Arribas JR, et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy- naïve adults with HIV-1 infection. AIDS. 2022;36(1):39–48.
   PubMed Web of Science ®Google Scholar
• Sax PE, Rockstroh JK, Luetkemeyer AF, et al. 380-4030 investigators. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV. Clin Infect Dis. 2020;ciaa988. DOI:10.1093/cid/ciaa988.
   Web of Science ®Google Scholar
• Molina JM, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus Abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 weeks results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e357–65.
   PubMed Web of Science ®Google Scholar
• Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e347–56.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Rizzardini G, Molina JM, et al. Bictegravir/Emtricitabine/Tenofovir Alafenamide in virologically suppressed people with HIV aged ≥ 65 years: week 48 results of a phase 3b, open-label trial. Infect Dis Ther. 2021;10(2):775–788.
   PubMed Web of Science ®Google Scholar
• Reynes J, Meftah N, Tuaillon E, et al. Dual regimen with dolutegravir and lamivudine maintains virologic suppression even in heavily treatment experienced HIV-infected patients: 96 weeks results from maintenance dolulam study. J Int AIDS Soc. 2016;19:68–69.
   Web of Science ®Google Scholar
• Baldin G, Ciccullo A, Borghetti A, et al. Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice. J Antimicrob Chemother. 2019;74(5):1461–1463.
   PubMed Web of Science ®Google Scholar
• Hidalgo-Tenorio C, Cortes LL, Gutierrez A, et al. Dolama study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed hiv-1 patients. Medicine (Baltimore). 2019;98(32):e16813.
   PubMed Web of Science ®Google Scholar
• Gagliardini R, Lorenzini P, Cozzi-Lepri A, et al. Effect of past virological failure on dolutegravir+lamivudine as maintenance regimen (0486). CROI 2020, Boston, 2020Mar8–11. Available from: https://www.croiconference.org/abstract/effect-of-past-virological-failure-on-dolutegravirlamivudine-as-maintenance-regimen/ (cited 2021 Jun 02).
   Google Scholar
• Galizzi N, Poli A, Galli L, et al. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients. Int J Antimicrob Agents. 2020;55(3):105893.
   PubMed Web of Science ®Google Scholar
• Ward D, Ramgopal M, Riedel DJ, et al. Real-world experience with dolutegravir-based two-drug regimens. AIDS Res Treat. 2020;2020:5923256.
   PubMed Web of Science ®Google Scholar
• van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020;71(8):1920–1929. /Protocol TANGO: Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO). Available at URL: https://clinicaltrials.gov/ct2/show/NCT03446573?term=TANGO+dolutegravir&draw=2&rank=1 (cited: 02/06/2021).
   PubMed Web of Science ®Google Scholar
• Capetti AF, Sterrantino G, Cossu MV, et al. Switch to dolutegravir plus rilpivirine dual therapy in cART-experienced subjects: an observational cohort. PLoS ONE. 2016;11(10):e0164753.
   PubMed Web of Science ®Google Scholar
• Gantner P, Cuzin L, Allavena C, et al. Dat’AIDS study group. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study. HIV Med. 2017;18(9):704–708.
   PubMed Web of Science ®Google Scholar
• Capetti AF, Cossu MV, Sterrantino G, et al. Dolutegravir plus rilpivirine as a switch option in cART-experienced patients: 96-week data. Ann Pharmacother. 2018;52(8):740–746.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Lupo S, Parks D, et al. 202094 sub-study investigators. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. AIDS. 2018;32(4):477–485.
   PubMed Web of Science ®Google Scholar
• Palacios R, Mayorga M, González-Domenech CM, et al. Safety and efficacy of dolutegravir plus rilpivirine in treatment-experienced HIV-infected patients: the DORIVIR study. J Int Assoc Provid AIDS Care. 2018;17:2325958218760847.
   Google Scholar
• Revuelta-Herrero JL, Chamorro-de-Vega E, Rodríguez-González CG, et al. Effectiveness, safety, and costs of a treatment switch to dolutegravir plus rilpivirine dual therapy in treatment-experienced HIV patients. Ann Pharmacother. 2018;52(1):11–18.
   PubMed Web of Science ®Google Scholar
• Casado JL, Monsalvo M, Fontecha M, et al. Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting. HIV Res Clin Pract. 2019;20(2):64–72.
   PubMedGoogle Scholar
• Ciccullo A, Baldin G, Capetti A, et al. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients. Antivir Ther. 2019;24(1):63–67.
   PubMed Web of Science ®Google Scholar
• Riccardi N, Del Puente F, Taramasso L, et al. Maintenance of viral suppression after optimisation therapy from etravirine plus raltegravir to rilpivirine plus dolutegravir in HIV-1-infected patients. J Int Assoc Provid AIDS Care. 2019;18:2325958218821657.
   Google Scholar
• Amor-García MÁ, Rodríguez-González CG, Chamorro-de-vega E, et al. Dolutegravir-based dual therapies in HIV pretreated patients: a real-life study in Madrid. Ann Pharmacother. 2021;10600280211038504. DOI:10.1177/10600280211038504.
   Web of Science ®Google Scholar
• Arancón Pardo A, Moreno Palomino M, Jiménez-Nácher I, et al. Real-world experience with two-drug regimens in HIV-1-infected patients beyond the indication of clinical trials: 48 weeks’ results. AIDS Res Hum Retroviruses. 2021;37(10):761–767.
   PubMed Web of Science ®Google Scholar
• Boswell R, Foisy MM, Hughes CA. Dolutegravir dual therapy as maintenance treatment in HIV-infected patients: a review. Ann Pharmacother. 2018;52(7):681–689.
   PubMed Web of Science ®Google Scholar
• Capetti AF, Cossu MV, Paladini L, et al. Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection. Expert Opin Pharmacother. 2018;19(1):65–77.
   PubMed Web of Science ®Google Scholar
• Clinical review report: dolutegravir/Rilpivirine (Juluca): (ViiV Healthcare): indication: as a complete regimen to replace the current antiretroviral regimen for the treatment of HIV-1 infection in adults who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per mL). [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jun. PMID: 30645063.
   Google Scholar
• Corado KC, Caplan MR, Daar ES. Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy. Drug Des Devel Ther. 2018;12:3731–3740.
   PubMed Web of Science ®Google Scholar
• Dowers E, Zamora F, Barakat LA, et al. Dolutegravir/rilpivirine for the treatment of HIV-1 infection. HIV AIDS (Auckl). 2018;10:215–224.
   PubMedGoogle Scholar
• Hester EK, Astle KD-R. Dual antiretroviral therapy for the treatment of HIV-1 infection. Ann Pharmacother. 2019;53(8):860–866.
   PubMed Web of Science ®Google Scholar
• Cento V, Perno CF. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: latest evidence from the literature on their efficacy and safety. J Glob Antimicrob Resist. 2020;20:228–237.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391(10123):839–849.
   PubMed Web of Science ®Google Scholar
• Aboud M, Orkin C, Podzamczer D, et al. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019;6(9):e576–87.
   PubMed Web of Science ®Google Scholar
• van Wyk J, Orkin C, Rubio R, et al. Brief report: durable suppression and low rate of virologic failure 3 years after switch to Dolutegravir + Rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and SWORD-2 randomized clinical trials. J Acquir Immune Defic Syndr. 2020;85(3):325–330.
   PubMed Web of Science ®Google Scholar
• Achhra AC, Mwasakifwa G, Amin J, et al. Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis. Lancet HIV. 2016;3(8):e351–60.
   PubMed Web of Science ®Google Scholar
• Nickel K, Halfpenny NJA, Snedecor SJ, et al. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis. BMC Infect Dis. 2021;21(1):222.
   PubMed Web of Science ®Google Scholar
• Reeves AA, Fuentes AV, Caballero J, et al. Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis. Sex Transm Infect. 2021;97(4):261–267.
   PubMed Web of Science ®Google Scholar
• Zhang K, Zhang Y, Liu X, et al. Three-drug regimens containing integrase inhibitor show good efficacy and safety in treatment-naïve patients with HIV-1: a bayesian analysis. Front Pharmacol. 2021;12:603068.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Hara N, Osa M, et al. Efficacy of switching to dolutegravir plus rilpivirine, the small-tablet regimen, in patients with dysphagia: two case reports. J Pharm Health Care Sci. 2017;3(1):23.
   PubMedGoogle Scholar
• ODOACRE Study Group. Fabbiani M, Rossetti B, Ciccullo A, et al. Efficacy and durability of two- vs three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: data from real-life ODOACRE cohort. HIV Med. 2021;22(9):843–853.
   PubMed Web of Science ®Google Scholar
• Argimón JM, Villa JJ. Métodos de investigación aplicados a la atención primaria de salud. Barcelona: Mosby/Doyma Libros; 1991.
   Google Scholar
• Rubio Terrés C. Diseño estadístico de ensayos clínicos. Med Clin (Barc). 1996;107(8):303–309.
   PubMedGoogle Scholar
• Note for guidance on statistical principles for clinical trials (CPMP/ICH/363/96). European Medicines Agency (EMEA). September, 1998. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf (cited 2021 Jun 02).
   Google Scholar
• Hulley SB, Cummings SR. Diseño de la investigación clínica. Un enfoque epidemiológico. Barcelona: Doyma; 1993.
   Google Scholar
• Tao X, Lu Y, Zhou Y, et al. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomised controlled trials. Int J Infect Dis. 2020;93:108–117.
   PubMed Web of Science ®Google Scholar
• Pilkington V, Hughes SL, Pepperrell T, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. AIDS. 2020;34(15):2259–2268.
   PubMed Web of Science ®Google Scholar
• Shapiro SH, Louis TA. Clinical trials. Issues and approaches. New York: Marcel Dekker; 1983.
   Google Scholar
• Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. Littelton: PSG Publishing Company; 1985.
   Google Scholar
• De Abajo FJ, Serrano Castro MA. Problemas prácticos en un ensayo clínico (I). In: García Alonso F, Bakke OM, editors. Metodología del ensayo clínico. Barcelona: Fundación Dr. Antonio Esteve; 1991. p. 11–20.
   Google Scholar
• Sacristán JA, Soto J, Galende I. Evaluación crítica de ensayos clínicos. Med Clin (Barc). 1993;100(20):780–787.
   PubMedGoogle Scholar
• Sackett DL, Haynes RB, Tugwell P. Clinical epidemiology. A basic science for clinical medicine. Boston: Little, Brown and Company; 1985. • Fundamentals on clinical epidemiology.
   Google Scholar
• Sacket DL, Richardson WS, Rosenberg W. Evidence-based medicine: how to practice and teach EBM. New York: Churchill Livingstone; 1997. • Fundamentals on Evidence-Based Medicine.
   Google Scholar
• Lewis SC, Warlow CP. How to spot bias and other potential problems in randomised controlled trials. J Neurol Neurosurg Psychiatry. 2004;75(2):181–187.
   PubMed Web of Science ®Google Scholar
• Panel de Expertos de GeSIDA y Plan Nacional sobre el SIDA. Documento de consenso de GeSIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (draft update 2022). GeSIDA/Ministerio de Sanidad, 2022.
   Google Scholar
• White K, Kulkarni R, Miller MD. Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients. J Antimicrob Chemother. 2015;70(9):2632–2638.
   PubMedGoogle Scholar
• Shu Y, Qiu C, Tu X, et al. Efficacy and safety of triple versus dolutegravir-based dual therapy in patients with HIV-1 infection: a meta-analysis of randomised controlled trials. AIDS Rev. 2021;23(3):133–142. 10.24875&AIDSREv.20000103.
   PubMed Web of Science ®Google Scholar
• Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128(1):305–310.
   PubMed Web of Science ®Google Scholar
• Ponce OJ, Alvarez-Villalobos N, Shah R, et al. What does expert opinion in guidelines mean? A meta-epidemiological study. Evid Based Med. 2017;22(5):164–169.
   PubMedGoogle Scholar
• Murad MH, Asi N, Alsawas M, et al. New evidence pyramid. Evid Based Med. 2016;21(4):125–127.
   PubMedGoogle Scholar
• Gagliardini R, Ciccullo A, Borghetti A, et al.; ARCA Study Group. Impact of the M184V resistance mutation on virological efficacy and durability of Lamivudine-Based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study. Open Forum Infect Dis. 2018;5(6):ofy113.
   PubMed Web of Science ®Google Scholar
• Santoro MM. Virological efficacy of switch to 3TC/DTG in real life cohort of suppressed HIV-1 patients with or without past m184V – The LAMRES study (#13). Reviews in Antiviral Therapy & Infectious Diseases 2, 2021, presented at European Meeting on HIV & Hepatitis, Virtual Meeting, 2021.
   Google Scholar
• Teira R, Diaz-Cuervo H, Aragão F, et al. Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV. PLoS ONE. 2021;16(4):e0249515.
   PubMed Web of Science ®Google Scholar
• PRISMA Group. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269.
   PubMed Web of Science ®Google Scholar
• Sun J, Lu H. Less is more: a novel single-tablet regimen with two-drugs, dolutegravir/lamivudine. Drug Discov Ther. 2021;15(4):225–226.
   PubMed Web of Science ®Google Scholar